Cardiotoxicity of Trastuzumab Emtansine (T-DM1): A Single-center Experience
dc.contributor.author | Acibuca, Aynur | |
dc.contributor.author | Sezer, Ahmet | |
dc.contributor.author | Yilmaz, Mustafa | |
dc.contributor.author | Sumbul, Ahmet Taner | |
dc.contributor.author | Demircan, Senol | |
dc.contributor.author | Muderrisoglu, Ibrahim Haldun | |
dc.contributor.author | Ozyilkan, Ozgur | |
dc.contributor.authorID | 0000-0002-3444-8845 | en_US |
dc.contributor.pubmedID | 34898302 | en_US |
dc.contributor.researcherID | ABG-4047-2020 | en_US |
dc.date.accessioned | 2022-06-23T07:12:04Z | |
dc.date.available | 2022-06-23T07:12:04Z | |
dc.date.issued | 2021 | |
dc.description.abstract | Objective New anti-cancer drugs promise to increased survival benefits and reduce adverse events. Trastuzumab emtansine (T-DM1) is a novel anti-human epidermal growth factor receptor 2 agent that has shown minimal cardiotoxicity in clinical trials. However, data on real-life outcomes are required. Methods A retrospective review of our center's medical records was performed, including female patients aged >= 18 years with a diagnosis of metastatic breast cancer who were treated with T-DM1. Descriptive statistics were used to investigate clinical features that could increase the risk of cardiotoxicity. Cardiotoxicity was determined by comparing pre and post-T-DM1 echocardiogram results and was defined as a decrease in the left ventricular ejection fraction (LVEF) >10% to below 55%. Results Data from 41 female patients with a mean age of 52 +/- 11.5 years were evaluated. A significant LVEF decrease (from 59% to 33%) was observed in one patient during T-DM1 treatment. Further investigation showed that this decrease was due to underlying coronary artery disease, and LVEF recovered to the baseline value after coronary revascularization. Conclusion T-DM1 seems to be safe in terms of cardiotoxicity. Real-life data with a larger sample size are still needed to confirm the cardiac safety of T-DM1. | en_US |
dc.identifier.endpage | 8 | en_US |
dc.identifier.issn | 0300-0605 | en_US |
dc.identifier.issue | 12 | en_US |
dc.identifier.scopus | 2-s2.0-85121351478 | en_US |
dc.identifier.startpage | 1 | en_US |
dc.identifier.uri | https://journals.sagepub.com/doi/pdf/10.1177/03000605211053755 | |
dc.identifier.uri | http://hdl.handle.net/11727/7122 | |
dc.identifier.volume | 49 | en_US |
dc.identifier.wos | 000730597300001 | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.1177/03000605211053755 | en_US |
dc.relation.journal | JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Breast cancer | en_US |
dc.subject | cardiotoxicity | en_US |
dc.subject | trastuzumab emtansine | en_US |
dc.subject | left ventricular ejection fraction | en_US |
dc.subject | echocardiogram | en_US |
dc.subject | metastatic breast cancer | en_US |
dc.title | Cardiotoxicity of Trastuzumab Emtansine (T-DM1): A Single-center Experience | en_US |
dc.type | article | en_US |